Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Familial primary pulmonary hypertension.
Langleben D. Langleben D. Chest. 1994 Feb;105(2 Suppl):13S-16S. doi: 10.1378/chest.105.2_supplement.13s. Chest. 1994. PMID: 8306801 Review. No abstract available.
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M. Langleben D, et al. Am Heart J. 2002 May;143(5):E4. doi: 10.1067/mhj.2002.121806. Am Heart J. 2002. PMID: 12040360 Clinical Trial.
The endothelin system in pulmonary hypertension.
Michel RP, Langleben D, Dupuis J. Michel RP, et al. Among authors: langleben d. Can J Physiol Pharmacol. 2003 Jun;81(6):542-54. doi: 10.1139/y03-008. Can J Physiol Pharmacol. 2003. PMID: 12839266 Review.
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D, Brock T, Dixon R, Barst R; STRIDE-1 study group. Langleben D, et al. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S80-4. doi: 10.1097/01.fjc.0000166207.74178.d0. J Cardiovasc Pharmacol. 2004. PMID: 15838366 Clinical Trial.
227 results